Search results for "Antibodies."

showing 10 items of 1857 documents

Anti-actin antibodies in celiac disease: correlation with intestinal mucosa damage and comparison of ELISA with the immunofluorescence assay.

2005

The presence in the sera of celiac disease (CD) patients of anti-actin autoantibodies (AAAs) has been suggested as a marker of severe intestinal villus atrophy (1). AAAs have been detected with an immunofluorescence (IF) technique and seem to contribute to villus cytoskeleton damage and to the pathogenesis of intestinal damage in CD (2). The aims of the present study were to evaluate the relationship between the presence of serum IgA AAAs and severity of intestinal mucosa damage in CD patients and to compare the IF assay with a new ELISA for IgA AAA determination. We enrolled 150 individuals in the study. IgA AAAs were assayed in 58 consecutive CD patients diagnosed between January and Dece…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAdolescentClinical Biochemistryanti-actin autoantibodieFluorescent Antibody TechniqueEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisGastroenterologyCoeliac diseasePrimary biliary cirrhosisIntestinal mucosaInternal medicinemedicineHumansIntestinal MucosaChildPediatric gastroenterologyAutoantibodiesbusiness.industryBiochemistry (medical)Intestinal villusAutoantibodyInfantMiddle Agedmedicine.diseaseActinsImmunoglobulin AFood intoleranceanti-actin autoantibodies; celiac disease; ELISAmedicine.anatomical_structureChild PreschoolFemaleELISAbusinessceliac disease
researchProduct

Antiendomysium antibodies assay in the culture medium of intestinal mucosa: an accurate method for celiac disease diagnosis

2011

Background Celiac disease (CD) diagnosis is becoming more difficult as patients with no intestinal histology lesions may also be suffering from CD. Aim To evaluate the diagnostic accuracy of antiendomysium (EmA) assay in the culture medium of intestinal biopsies for CD diagnosis. Patients and methods The clinical charts of 418 patients with CD and 705 non-CD controls who had all undergone EmA assay in the culture medium were reviewed. Results EmA assay in the culture medium had a higher sensitivity (98 vs. 80%) and specificity (99 vs. 95%) than serum EmA/antibodies to tissue transglutaminase (anti-tTG) assay. All patients with CD who were tested as false-negatives for serum EmA and/or anti-…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAdolescentTissue transglutaminaseDuodenumBiopsyMuscle Fibers Skeletalceliac disease culture system diagnosis intestinal histology serum antiendomysiumDiseaseHuman leukocyte antigenGastroenterologyAntiendomysium antibodiesTissue Culture TechniquesYoung AdultIntestinal mucosaInternal medicineBiopsyMedicineHumansVillous atrophyIntestinal MucosaChildFalse Negative ReactionsAgedAutoantibodiesTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryGastroenterologyInfantMiddle AgedCulture MediaCeliac DiseaseChild Preschoolbiology.proteinFemaleAntibodybusinessEpidemiologic MethodsBiomarkers
researchProduct

Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: a predictive i…

1998

The indications for liver biopsy in anti-HCV-positive patients with persistently normal alanine aminotransferase levels are not clearly established. Recent studies have correlated the presence of abdominal lymphoadenomegaly with disease severity in patients with chronic hepatitis C. Our study aimed to evaluate the frequency of abdominal lymphoadenomegaly in an anti-HCV positive blood donor population with persistently normal alanine aminotransferase and the relationship of abdominal lymphoadenomegaly with the severity of liver changes.Eighty-six anti-HCV positive blood donors (58 M, 28 F) with normal alanine aminotransferase were followed up for a median of 31 months (range 12-50). To evalu…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaLogistic ModelAdolescentPrognosiHepatitis C virusHepacivirusBiopsyPopulationBlood Donorsmedicine.disease_causeGastroenterologyRegression AnalysiInternal medicineAbdomenmedicineHumanseducationLymphatic Diseasesabdominal lymph nodes; chronic hepatitis c; normal transaminase; ultrasoundUltrasonographyeducation.field_of_studyHepatologymedicine.diagnostic_testbiologybusiness.industryUltrasoundAlanine TransaminaseHepatitis C AntibodiesHepatitis C ChronicMiddle Agedbiology.organism_classificationPrognosismedicine.anatomical_structureLogistic ModelsLiverLiver biopsyAbdomenRegression AnalysisFemaleViral diseaseLiver functionLymphatic DiseaseHepatitis C AntibodiebusinessHumanJournal of hepatology
researchProduct

Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: A prospective study

2002

Abstract Background: Most studies of anti-transglutaminase (anti-tTG) assays have considered preselected groups of patients. This study compared the sensitivity, specificity, and predictive value of an immunofluorescence method for anti-endomysial antibodies (EmAs) and two anti-tTG ELISAs, one using guinea pig tTG (gp-tTG) and the other human tTG (h-tTG) as antigen, in consecutive patients investigated for suspected celiac disease (CD). Methods: We studied 207 consecutive patients (99 men, 108 women; age range, 17–84 years) who underwent intestinal biopsy for suspected CD. Patients presented with one or more of the following: weight loss, anemia, chronic diarrhea, abdominal pain, dyspepsia,…

AdultMalemedicine.medical_specialtyPathologyanti-endomysial antibodieSettore MED/09 - Medicina InternaAdolescentTissue transglutaminaseAnemiaClinical BiochemistryGuinea PigsEnzyme-Linked Immunosorbent AssayChronic liver diseaseGastroenterologyCoeliac diseaseEsophagusAntibody SpecificityPredictive Value of TestsInternal medicineImmunopathologymedicineAnimalsHumansanti-transglutaminase; assays; anti-endomysial antibodies; celiac diseaseProspective StudiesProspective cohort studyAgedAutoantibodiesAged 80 and overTransglutaminasesbiologybusiness.industryBiochemistry (medical)HaplorhiniassayMiddle Agedmedicine.diseaseEndomysiumImmunoglobulin ACeliac Diseasemedicine.anatomical_structurePredictive value of testsbiology.proteinFemaleanti-transglutaminasebusiness
researchProduct

How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy.

2005

Abstract The epidemiology of pertussis in Italy is described by using data from the statutory notification system and from seroepidemiology studies. Starting from the 1990s, the incidence of pertussis in Italy has shown a sharp decline and is now at the lowest level ever reached. During this time period vaccination coverage has increased from 88% in 1998 to 95% in 2003. In 1996–97, the prevalence of subjects with levels of IgG antibodies against PT greater than 2 EU/ml was 77.6%. The increase in vaccination coverage will probably change the pattern of disease transmission and increase the number of susceptible adults, unless administration of booster doses to adolescents and adults is consi…

AdultMalemedicine.medical_specialtyPediatricsAdolescentWhooping CoughImmunization SecondaryMandatory ProgramsMass VaccinationPertussiSeroepidemiologic StudiesEpidemiologyMedicineHumansPertussis vaccinationRegistriesChildWhooping coughSeroepidemiologyVaccination coveragePertussis VaccineBooster (rocketry)General VeterinaryGeneral Immunology and Microbiologybusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthAge FactorsInfantmedicine.diseaseAntibodies BacterialInfectious DiseasesItalyVaccination coverageChild PreschoolPopulation SurveillanceImmunologyMolecular MedicineFemalebusinessTos ferinaDisease transmissionVaccine
researchProduct

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

1995

Aplastic anemia is occasionally caused by viral hepatitis, hepatitis C virus being the most important factor. Pathogenetically, decreased bone marrow function, abnormalities of the bone marrow microenvironment, and immune-mediated suppression of hematopoiesis are important. Hepatitis C virus infection is associated with a variety of extrahepatic manifestations including autoimmune features like cryoglobulinemia, Sjogren's syndrome, and autoimmune hepatitis. Here we report the case of a 42-year-old man with aplastic anemia due to posttransfusional hepatitis C virus infection associated with cryoglobulinemia and LKM-1 autoantibodies. Following a triple immunosuppressive therapy, there was a c…

AdultMalemedicine.medical_specialtyPhysiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeBone MarrowInternal medicinemedicineHumansAplastic anemiaAutoantibodiesbusiness.industryGastroenterologyAutoantibodyAnemia AplasticTransfusion ReactionHepatologymedicine.diseaseVirologyCryoglobulinemiaHepatitis Cmedicine.anatomical_structureCryoglobulinemiaImmunologyBone marrowbusinessViral hepatitisDigestive diseases and sciences
researchProduct

Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily.

2009

The virus that causes Kaposi sarcoma, KS-associated herpesvirus (KSHV, also known as human herpesvirus 8) has an unusual distribution and poorly characterized modes of transmission. To clarify these issues, socio-demographic correlates of KSHV seroprevalence were examined in a population-based study. In 1,154 randomly sampled adults (aged 32- 92, mean 71 years) throughout Sicily, KSHV antibodies were detected with four assays and a conservative algorithm. Seroprevalence was re-weighted to the population. Odds ratios with 95% confidence intervals (OR, CI) from multivariate logistic regression were used to estimate associations of seroprevalence with interview data. KSHV seroprevalence was 8.…

AdultMalemedicine.medical_specialtyPopulationLogistic regressionAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataArticleSerologyRisk FactorsSeroepidemiologic StudiesVirologyEpidemiologymedicineSeroprevalenceGammaherpesvirinaeHumanseducationSicilyAgedAged 80 and overeducation.field_of_studybiologybusiness.industryOdds ratioHerpesviridae InfectionsMiddle Agedbiology.organism_classificationVirologyKSHV seroprevalence socio-economic correlates elderly SicilyConfidence intervalInfectious DiseasesSocioeconomic FactorsHerpesvirus 8 HumanFemalebusiness
researchProduct